Pharvaris

IPO

Pioneering Science for Patient Choice

Public · Zug, Switzerland · Founded 2015 · $216.0M raised

Headquarters
Zug
Employees
51–200
Founded
2015
Business Model
B2B
Total Funding
$216.0M
Last Round
$70.0M Private EquityJun 2023
Rounds
3
Type
Public

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

Pharvaris is a late-stage biopharmaceutical company developing novel oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE) attacks. Its lead asset, deucrictibant, is in two pivotal Phase 3 trials (CHAPTER-3 for prophylaxis and RAPIDe-3 for on-demand treatment), aiming to deliver injectable-like efficacy with the convenience of oral administration.

Summary

Pharvaris is a Biotech company based in Zug, Switzerland, founded in 2015. It has raised $216.0M in total across 3 rounds, most recently a $70.0M Private Equity round in Jun 2023.

Tech & App Stack

4 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding & Exit History

Private EquityPrivate PlacementJun 2023
$70.0M

Sign up to see all 4 events

Funding: Series B through Private Equity. Amounts, valuations, and investors where available.

Similar Companies

Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Life Sciences, Biotech
Series ATotal funding$3.0BJan 2022
BridgeBioIPO

BridgeBio develops treatments for genetic conditions through autonomous condition-focused teams s...

San Francisco Bay Area, United States201–500Biotech, Healthcare
Growth EquityTotal funding$2.7BJul 2026
AsymchemIPO

Asymchem is a pharmaceutical CDMO providing R&D, chemistry, manufacturing, and control services t...

Tianjin, China5001–10000Biotech, Drug Discovery
Private EquityTotal funding$2.3BFeb 2020
Calico

Calico researches human aging using advanced technologies and model systems, applying that knowle...

South San Francisco, United States201–500Biotech, Healthcare
Corporate RoundTotal funding$2.3BJun 2018
Sana BiotechnologyIPO

Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...

Seattle, United States201–500Biotech, Healthcare
Series DTotal funding$1.4BJun 2020
CertaraIPO

Global biosimulation software and services company accelerating drug development for 2,000+ bioph...

Radnor, United States1001–5000Biotech, Healthcare
Private EquityTotal funding$1.3BDec 2022

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Pharvaris on Indexed.vc
<a href="https://indexed.vc/companies/pharvaris"><img src="https://indexed.vc/api/badge/company/pharvaris" alt="Pharvaris on Indexed.vc" width="260" height="76" /></a>